Beijing-based second-generation sequencing technology platform Cygnus Bio has reportedly raised “hundreds of millions” of renminbi in a Series C+ financing round. The round was led by Source Code Capital, with contributions from CCB Private Equity Investment, E-town Capital, Founder H Fund, and Lotus Lake Capital. The funds will be used to enhance research and development (R&D), original innovation, the launch of medium and large flux sequencing platforms, regulatory filing for Category III devices, marketing and commercialization capabilities, and exploration and expansion of commercial application scenarios with industry chain partners.
About Cygnus Bio
Founded in 2015, Cygnus Bio is known for its desktop S100 gene sequencer. This investment will further strengthen the company’s position in the sequencing technology market, enabling it to develop new products and expand its market reach.-Fineline Info & Tech
